Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Cannabinoid biomedicine research programme launched

Research

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.

Image courtesy of Shutterstock

The programme aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.

Through an initial investment of up to £10 million provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.

Read more (Oxford University website) 

Similar stories

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Unique clinical imaging dataset released for artificial intelligence research to accelerate diagnosis of prostate cancer

How artificial intelligence is shaping medical imaging

Dr Qiang Zhang of the Radcliffe Department of Medicine explains how artificial intelligence is being used to help researchers and physicians interpret medical imaging.

Researchers describe how cancer cells can defend themselves from the consequences of certain genetic defects

Researchers in Department of Physiology, Anatomy and Genetics have identified a rescue mechanism that allows cancers to overcome the consequences of inactivating mutations in critically important genes.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.